Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.

Cardio Diagnostics Holdings Inc. has announced that starting from April 3, 2024, its senior management will use a new set of materials for presentations to current and potential investors. These materials are part of the March 2024 Investor Presentation, which is now incorporated into the company's Form 8-K filing with the SEC and will also be available on Cardio Diagnostics' website. The company, listed on The Nasdaq Stock Market LLC under the symbol CDIO for its common stock and CDIOW for its redeemable warrants, is classified as an emerging growth company. The information provided in the Investor Presentation is not considered filed for SEC purposes and is not incorporated by reference into any registration statement as per the Securities Exchange Act of 1934, except as explicitly stated in such filings.